1685 related articles for article (PubMed ID: 30463454)
1. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
2. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
3. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
4. SGLT2 inhibition and heart failure-current concepts.
Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the failing heart and the impact of SGLT2 inhibitors.
Garcia-Ropero A; Santos-Gallego CG; Zafar MU; Badimon JJ
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):275-285. PubMed ID: 30822172
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Pancholia AK
Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
[TBL] [Abstract][Full Text] [Related]
7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Ren DY; Zhang Y
Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
11. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
13. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.
Wojcik C; Warden BA
Curr Cardiol Rep; 2019 Sep; 21(10):130. PubMed ID: 31522263
[TBL] [Abstract][Full Text] [Related]
16. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
Fioretto P; Avogaro A
Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
[TBL] [Abstract][Full Text] [Related]
18. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B; Li S; Kang B; Zhou J
Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
[TBL] [Abstract][Full Text] [Related]
19. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
20. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]